Stiripentol
Overview
Stiripentol is an anticonvulsant medication used to treat seizures in individuals with Dravet syndrome, a severe form of epilepsy. It works by stabilizing neuronal activity and has been shown to enhance the effect of other antiepileptic drugs.
API suppliers (5)
Suppliers of Stiripentol evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 4 of 5 suppliers.
2 of 5 hold a GMP certificate on record in the EU or UK registers
- SS PHARMA LLCIndia1 active DMF
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
- ALP PHARM BEIJING CO LTD1 active DMF
- METROCHEM API PRIVATE LTDIndia1 active DMF
- Torrent PharmaceuticalsIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (4 approved US products), the latest listed US patent on Stiripentol expires — and exclusivity 14 Jul 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Stiripentol? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.